Key facts
- This page summarizes Ph.D. Noubar B. Afeyan's Form 4 filing for Generate Biomedicines, Inc. (GENB).
- 19 reported transactions and 11 derivative rows are listed below.
- Accepted by SEC: 02 Mar 2026, 17:52.
Ph.D. Noubar B. Afeyan - 26 Feb 2026 Form 4 Insider Report for Generate Biomedicines, Inc. (GENB)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- GENB
- Reported as of
- 26 Feb 2026
- Net transaction value
- +$75,000,000
- SEC form
- 4
- Accepted by SEC
- 02 Mar 2026, 17:52:09 UTC
- Prior SEC filing
- 15 Dec 2025
- Next SEC filing
- 08 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Noubar B. Afeyan, Ph.D.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ph.D. Noubar B. Afeyan filed Form 4 for Generate Biomedicines, Inc. (GENB) on 02 Mar 2026.
Change
- Previous filing in this sequence was filed on 15 Dec 2025.
- Current net transaction value: +$75,000,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (8)
CIK 0001222012
Primary reporting owner
AFEYAN NOUBAR
- Relationship
- Director, 10%+ Owner
- Address
- 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE
- Signature
- /s/ Noubar B. Afeyan, Ph.D.
- Signature date
- 02 Mar 2026
CIK 0001400240
Flagship Pioneering, LLC
- Relationship
- 10%+ Owner
- Address
- 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE
- Signature
- Flagship Pioneering, LLC, By: /s/ Noubar B. Afeyan, Ph.D., Title: Sole Member and Manager of Manager
- Signature date
- 02 Mar 2026
CIK 0001860060
Flagship VentureLabs VI Manager LLC
- Relationship
- 10%+ Owner
- Address
- 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE
- Signature
- Flagship VentureLabs VI Manager LLC, By: /s/ Noubar B. Afeyan, Ph.D., Title: Sole Member and Manager of Manager of Manager
- Signature date
- 02 Mar 2026
CIK 0001724957
Flagship Pioneering Fund VI General Partner LLC
- Relationship
- 10%+ Owner
- Address
- 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE
- Signature
- Flagship Pioneering Fund VI General Partner LLC, By: /s/ Noubar B. Afeyan, Ph.D., Title: Sole Member and Manager of Manager of Manager
- Signature date
- 02 Mar 2026
CIK 0001805917
Flagship Pioneering Fund VII General Partner LLC
- Relationship
- 10%+ Owner
- Address
- 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE
- Signature
- Flagship Pioneering Fund VII General Partner LLC, By: /s/ Noubar B. Afeyan, Ph.D., Title: Sole Member and Manager of Manager of Manager
- Signature date
- 02 Mar 2026
CIK 0001780951
Nutritional Health LTP Fund General Partner LLC
- Relationship
- 10%+ Owner
- Address
- 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE
- Signature
- Nutritional Health LTP Fund General Partner LLC, By: /s/ Noubar B. Afeyan, Ph.D., Title: Sole Member and Manager of Manager of Manager
- Signature date
- 02 Mar 2026
CIK 0001826217
Flagship Pioneering Special Opportunities Fund II General Partner LLC
- Relationship
- 10%+ Owner
- Address
- 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE
- Signature
- Flagship Pioneering Special Opportunities Fund II General Partner LLC, By: /s/ Noubar B. Afeyan Ph.D., Title: Sole Member and Manager of Manager of Manager
- Signature date
- 02 Mar 2026
CIK 0001860059
FPN General Partner LLC
- Relationship
- 10%+ Owner
- Address
- 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE
- Signature
- FPN General Partner LLC, By: /s/ Noubar B. Afeyan, Ph.D., Title: Sole Member and Manager of Manager of Manager
- Signature date
- 02 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GENB
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +12,723,940
- Change %
- Price
- Shares after
- 12,723,940
- Date
- 02 Mar 2026
- Ownership
- By Flagship Pioneering Fund VI, L.P.
- Footnotes
- F1, F2
GENB
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +13,702,224
- Change %
- Price
- Shares after
- 13,702,224
- Date
- 02 Mar 2026
- Ownership
- By Flagship Pioneering Fund VII, L.P.
- Footnotes
- F1, F3
GENB
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +987,491
- Change %
- Price
- Shares after
- 987,491
- Date
- 02 Mar 2026
- Ownership
- By Nutritional Health LTP Fund, L.P.
- Footnotes
- F1, F4
GENB
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +2,777,752
- Change %
- Price
- Shares after
- 2,777,752
- Date
- 02 Mar 2026
- Ownership
- By Flagship Pioneering Special Opportunities Fund II, L.P.
- Footnotes
- F1, F5
GENB
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +2,777,752
- Change %
- Price
- Shares after
- 2,777,752
- Date
- 02 Mar 2026
- Ownership
- By FPN II, L.P.
- Footnotes
- F1, F6
GENB
transaction
Common Stock
Purchase
- Transaction value
- $25,000,000
- Shares
- +1,562,500
- Change %
- +11%
- Price
- $16.00
- Shares after
- 15,264,724
- Date
- 02 Mar 2026
- Ownership
- By Flagship Pioneering Fund VII, L.P.
- Footnotes
- F3
GENB
transaction
Common Stock
Purchase
- Transaction value
- $25,000,000
- Shares
- +1,562,500
- Change %
- +56%
- Price
- $16.00
- Shares after
- 4,340,252
- Date
- 02 Mar 2026
- Ownership
- By FPN II, L.P.
- Footnotes
- F6
GENB
transaction
Common Stock
Purchase
- Transaction value
- $25,000,000
- Shares
- +1,562,500
- Change %
- Price
- $16.00
- Shares after
- 1,562,500
- Date
- 02 Mar 2026
- Ownership
- By Pioneering Medicines 02, LLC
- Footnotes
- F7
GENB
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 25,016,458
- Date
- 26 Feb 2026
- Ownership
- By Flagship VentureLabs VI, LLC
- Footnotes
- F8
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GENB
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +29,561
- Change %
- Price
- $0.000000
- Shares after
- 29,561
- Date
- 26 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 29,561
- Exercise price
- $16.00
- Footnotes
- F9
GENB
transaction
Derivative
Series A Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -18,483,785
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 02 Mar 2026
- Ownership
- By Flagship Pioneering Fund VI, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 12,168,390
- Exercise price
- Footnotes
- F1, F2
GENB
transaction
Derivative
Series A Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -17,016,215
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 02 Mar 2026
- Ownership
- By Flagship Pioneering Fund VII, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 11,202,248
- Exercise price
- Footnotes
- F1, F3
GENB
transaction
Derivative
Series A Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -1,500,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 02 Mar 2026
- Ownership
- By Nutritional Health LTP Fund, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 987,491
- Exercise price
- Footnotes
- F1, F4
GENB
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -843,881
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 02 Mar 2026
- Ownership
- By Flagship Pioneering Fund VI, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 555,550
- Exercise price
- Footnotes
- F1, F2
GENB
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -1,265,822
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 02 Mar 2026
- Ownership
- By Flagship Pioneering Fund VII, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 833,325
- Exercise price
- Footnotes
- F1, F3
GENB
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -2,953,586
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 02 Mar 2026
- Ownership
- By Flagship Pioneering Special Opportunities Fund II, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 1,944,427
- Exercise price
- Footnotes
- F1, F5
GENB
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -2,109,704
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 02 Mar 2026
- Ownership
- By FPN II, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 1,388,876
- Exercise price
- Footnotes
- F1, F6
GENB
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -2,531,644
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 02 Mar 2026
- Ownership
- By Flagship Pioneering Fund VII, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 1,666,651
- Exercise price
- Footnotes
- F1, F3
GENB
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -1,265,822
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 02 Mar 2026
- Ownership
- By Flagship Pioneering Special Opportunities Fund II, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 833,325
- Exercise price
- Footnotes
- F1, F5
GENB
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -2,109,704
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 02 Mar 2026
- Ownership
- By FPN II, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 1,388,876
- Exercise price
- Footnotes
- F1, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 9 footnotes
Footnote F1
Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
Footnote F2
Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date.
Footnote F3
Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
Footnote F4
Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
Footnote F5
Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
Footnote F6
Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
Footnote F7
Securities held by Pioneering Medicine 02, LLC ("PM02"). Charles R. Carelli, Jr., Chief Financial Officer of Flagship Pioneering, is the sole manager of PM02, and Flagship Fund VII is its majority equity holder. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
Footnote F8
Securities held by Flagship VentureLabs VI LLC ("VentureLabs VI"). Flagship VentureLabs VI Manager LLC ("VentureLabs VI Manager") is the manager of VentureLabs VI. Flagship Pioneering is the manager of VentureLabs VI Manager. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
Footnote F9
The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.
SEC remarks
Form 2 of 2: This is the second of two Forms 4 being filed relating to the same event. The Form 4 is being split into two filings because there are more than 10 Reporting Persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 Reporting Persons. Each Form 4 is filed by Designated Filer Noubar Afeyan.